Non-communicable diseases (NCDs) thrive on oxidative stress, an imbalance of reactive oxygen species. This review delves into the crucial interplay between antioxidant enzymes and dietary antioxidants.
According to the World Health Organization (WHO), dementia is the third leading cause of mortality in Europe and the seventh globally, with a societal cost in Europe estimated to be €392bn in 2019. By 2025, 9.1 million people will be living with dementia in the European Union, rising to 14.3 million in 2050. We discuss dementia care provision with Alzheimer Europe.
Cambridge Vision Technology utilises AI-based technology to detect Alzheimer’s disease early on by using ocular biomarkers. They emphasise the importance of early detection of dementia to improve clinical outcomes for disease therapies and to maximise the economic and societal impact of this innovative new technology.
Researchers at the Perelman School of Medicine at the University of Pennsylvania have reported improvements in vision among patients with a rare inherited condition, following gene therapy.
The latest European Society of Cardiology (ESC) guidelines on chronic coronary syndromes (CCS) mark a significant shift in how cardiologists approach and treat heart conditions.
Dr Rayaz A Malik, Professor of Medicine at Weill Cornell Medicine-Qatar, discusses the challenges and impact of misdiagnosis and late diagnosis in type 1 diabetes.
Quantified Imaging, originating from the University of Nottingham, specialises in advanced MRI techniques to improve dementia care, diagnosis, monitoring, and treatment.
Symptoms of Monkeypox can take 5 to 21 days to appear, so it's important to be aware of the signs during this time and remain in isolation as it is contagious.
A groundbreaking new tool, The Glaucoma Field Defect Classifier (GFDC), developed by eye specialists at Addenbrooke’s Hospital, could transform glaucoma diagnosis and help change the way its managed worldwide.
Open Access Government discusses the prevalence of neglected tropical diseases, including barriers to awareness and the need to scale up effective interventions.
Despite affecting a significant portion of the population, the impact of rheumatic and musculoskeletal diseases (RMDs) is often underestimated, with many people living with RMDs, and their families, in need of greater care and support. Lynne Woolley at Versus Arthritis spoke to Lorna Rothery about the physical and psychological challenges of RMDs and what can be done.
